Persevere^TM Therapeutics is a US company formed in February 2025 with the intent to acquire the oncology program of Panavance Therapeutics. 

Persevere has signed an exclusive term sheet with Panavance’s parent company to acquire all intellectual property and related assets to advance the clinical development of misetionamide (GP-2250) , a novel small molecule, in the field of oncology.

Persevere is currently seeking initial financing to complete the acquisition.

For more information about Panavance Therapeutics
www.panavance.com

To contact Persevere, please email
persevere.therapeutics1@gmail.com